Literature DB >> 21287298

RNAi-mediated downregulation of NOB1 suppresses the growth and colony-formation ability of human ovarian cancer cells.

Yang Lin1, Shuai Peng, Hansong Yu, Hong Teng, Manhua Cui.   

Abstract

Nin one binding protein (NOB1p), encoded by the NOB1 gene, is a crucial molecule in the maturation of the 20S proteasome and protein degradation. The present study evaluates whether NOB1 is an appropriate molecular target for cancer gene therapy. In two ovarian cancer cell lines, SKOV3 and HEY, NOB1 expression was knocked down by a lentiviral short hairpin RNA (shRNA) delivery system. The RNA interference (RNAi)-mediated the downregulation of NOB1 expression markedly reduced the proliferative and colony-formation ability of ovarian cancer cells. Additionally, NOB1 shRNA-expressing lentivirus-treated ovarian cancer cells tended to arrest in the G0/G1 phase. These results suggested that NOB1 may act as an oncogenic factor in ovarian cancer and could be a potential molecular target for ovarian cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21287298     DOI: 10.1007/s12032-010-9808-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  17 in total

Review 1.  Regulatory subunit interactions of the 26S proteasome, a complex problem.

Authors:  K Ferrell; C R Wilkinson; W Dubiel; C Gordon
Journal:  Trends Biochem Sci       Date:  2000-02       Impact factor: 13.807

Review 2.  The proteasome and its role in nuclear protein maintenance.

Authors:  Nicolle Bader; Tobias Jung; Tilman Grune
Journal:  Exp Gerontol       Date:  2007-04-10       Impact factor: 4.032

Review 3.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

4.  Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.

Authors:  R Chiarle; L M Budel; J Skolnik; G Frizzera; M Chilosi; A Corato; G Pizzolo; J Magidson; A Montagnoli; M Pagano; B Maes; C De Wolf-Peeters; G Inghirami
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

5.  Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis.

Authors:  S Rogers; R Wells; M Rechsteiner
Journal:  Science       Date:  1986-10-17       Impact factor: 47.728

6.  Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85.

Authors:  A Ciechanover; D Finley; A Varshavsky
Journal:  Cell       Date:  1984-05       Impact factor: 41.582

7.  Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.

Authors:  A B Sparks; P J Morin; B Vogelstein; K W Kinzler
Journal:  Cancer Res       Date:  1998-03-15       Impact factor: 12.701

8.  Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing.

Authors:  M Shirane; Y Harumiya; N Ishida; A Hirai; C Miyamoto; S Hatakeyama; K Nakayama; M Kitagawa
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

9.  The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data.

Authors:  Vivian G Oehler; Ka Yee Yeung; Yongjae E Choi; Roger E Bumgarner; Adrian E Raftery; Jerald P Radich
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

10.  Nob1p is required for biogenesis of the 26S proteasome and degraded upon its maturation in Saccharomyces cerevisiae.

Authors:  Yoshiko Tone; Akio Toh-E
Journal:  Genes Dev       Date:  2002-12-15       Impact factor: 11.361

View more
  24 in total

1.  Knockdown of NOB1 expression inhibits the malignant transformation of human prostate cancer cells.

Authors:  Xiangmin Zhang; Dongxu Zhang; Fajun Qu; Yi Hong; Jianwei Cao; Xiuwu Pan; Lin Li; Yi Huang; Hai Huang; Lei Yin; Lu Chen; Jizhong Ren; Zhijun Wang; Danfeng Xu; Xingang Cui
Journal:  Mol Cell Biochem       Date:  2014-08-29       Impact factor: 3.396

2.  NOB1 is essential for the survival of RKO colorectal cancer cells.

Authors:  Xiao-Wen He; Tao Feng; Qiao-Ling Yin; Yuan-Wei Jian; Ting Liu
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

3.  MicroRNA-215 targets NOB1 and inhibits growth and invasion of epithelial ovarian cancer.

Authors:  Yang Lin; Yang Jin; Tianmin Xu; Shunqing Zhou; Manhua Cui
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

4.  Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells.

Authors:  Jia-xi Song; Wang-li Cao; Fang-qiu Li; Li-ning Shi; Xuan Jia
Journal:  Med Oncol       Date:  2011-12-24       Impact factor: 3.064

5.  Evaluation of NIN/RPN12 binding protein inhibits proliferation and growth in human renal cancer cells.

Authors:  Jian-wei Jia; Ai-qin Liu; Yun Wang; Fen Zhao; Li-ling Jiao; Jun Tan
Journal:  Tumour Biol       Date:  2014-11-26

6.  Lentivirus vector-mediated knockdown of erythropoietin-producing hepatocellular carcinoma receptors B4 inhibits laser-induced choroidal neovascularization.

Authors:  Jing Du; Wei Zhao; Yusheng Wang; Yan Cai
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-04       Impact factor: 2.671

7.  Anticancer activity of NOB1-targeted shRNA combination with TRAIL in epithelial ovarian cancer cells.

Authors:  Yang Lin; Tianmin Xu; Hong Teng; Manhua Cui
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Nin one binding protein expression as a prognostic marker in prostate carcinoma.

Authors:  G Liu; D Shen; L Jiao; Y Sun
Journal:  Clin Transl Oncol       Date:  2014-02-04       Impact factor: 3.405

9.  Clinical significance of NOB1 expression in breast infiltrating ductal carcinoma.

Authors:  Xiao-Yu Li; Qi-Feng Luo; Jia Li; Chuan-Kui Wei; Xiang-Jie Kong; Jun-Feng Zhang; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

10.  Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma.

Authors:  Jian-Ping Che; Wei Li; Yang Yan; Min Liu; Guang-Chun Wang; Qian-Yu Li; Bin Yang; Xu-Dong Yao; Jun-Hua Zheng
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.